This breakthrough technology uses ultrasonic energy guided by magnetic resonance or ultrasound imaging to treat tissue deep in the body without incisions or radiation. Multiple intersecting beams of ultrasound are directed and concentrated on a target as small as a grain of rice, much like a magnifying glass can focus multiple beams of light on a single point.
Focused ultrasound is currently approved in the U.S. to treat uterine fibroids and bone metastases, and there are a growing number of clinical applications in various stages of research and development around the world, including Parkinson’s disease, essential tremor, neuropathic pain, breast and prostate cancer, and brain tumors.
This breakthrough technology uses ultrasonic energy guided by magnetic resonance or ultrasound imaging to treat tissue deep in the body without incisions or radiation.
How much longer do we have to wait for the Focal 1 to be commissioned in the U.S.?
Sponsors and Collaborators
Galena Biopharma, Inc.
Principal Investigator: Elizabeth A Mittendorf, MD,FACS M.D. Anderson Cancer Center
My money is on Elizabeth A. Mittendorf, MD, FACS.
My perception also, TA evidently wants to build out. When they have decided they are big enough then the stock price will escalate above the $10-$15 range. All about growth right now.
The names sure do pop up. Again, I am looking for $15 or close to it. The economy should pick up a little with the low gas prices putting $$ in peoples spendable budget, trucking has stopped complaining about the cost of diesel.
There was a nike commercial out a few years ago that pervaded the American culture it may be appropriate here and now, NO FEAR, NO FEAR, NO FEAR
We have rode this horse for years now, the end is in sight and we must maintain our composure. As we near the finish of this epic journey let us remember not 1 of the recent clinical trial for Neuvax has been negative. The market has turned sour, management has not been altogether honest but management is but the conduit thru which medical technology (drugs) can reach the marketplace and people in need.
If all you have alluded to were to be true the70th event, go to completion or a positive statement should put the shorts in an unenviable position. However it appears Management again pull the rug out from under the shareholders.
The U.S. is a large country with many, many many sales possibilities. Not just the hospitals in Boise Idaho or
Saginaw Michigan but all the urology clinics which are large enough to be able to afford a machine. Countries in Europe will only have a few machines not like the U. S. if sales boom. I think edap should saturate the market from Oregon all the way to Maine. A sales force is needed, is it worth 1 million shares plus expenses? It will be approved. Next in line will be upgrading ability to manufacture the machines, more shares.
However, without those decisions being made Edap will flounder.
I suppose the proof will have to be in the pudding, good clinical results are one thing, great clinical results will have whipped cream and a cherry on top. Will not be long one way or the other , cake or porridge, what a possibility.
Cancer Treatment Vaccines
Cancer treatment vaccines target cancer cells themselves. They contain cancer cells, parts of cells, or antigens to stop cancer from growing. They treat cancer cells by activating your body’s arsenal of leukocytes to mount an immune response against specific types of cancer cells. The goal is to destroy the abnormal cells that haven’t been killed by other forms of cancer treatment.
Trouble is, cancer cells are sly. They have ways of masking themselves so your body doesn’t know they’re dangerous. They can also protect themselves from your body’s own immune response. As a result, it’s easier to prevent cancer with a vaccine than to treat it.
That is what Neuvax is all about, preventing the return of breast cancer